10 results found
Frazer A, Bunning RA, Thavarajah M, et al., 1994, Studies on type II collagen and aggrecan production in human articular chondrocytes in vitro and effects of transforming growth factor-beta and interleukin-1beta., Osteoarthritis Cartilage, Vol: 2, Pages: 235-245, ISSN: 1063-4584
Type II collagen and aggrecan are major components of the extracellular matrix of articular cartilage. Their biosynthesis and catabolism are regulated by chondrocytes. They may be used as markers of chondrocyte phenotype for cells cultured in vitro. Type II collagen gene expression was detected by amplification of type II collagen-specific sequences, using cDNA produced by reverse transcription of mRNA extracted from freshly isolated and cultured human articular chondrocytes by the polymerase chain reaction (PCR). The synthesis of gene product was confirmed by immunohistochemical localization of type II collagen in cartilage sections and in cultured chondrocytes. Aggrecan core protein was also immunolocalized in cartilage sections and in chondrocytes in culture. Expression of type II collagen or aggrecan was not detected immunohistochemically in skin or bone. These results demonstrate that human articular chondrocytes can be characterized in culture, by the combined application of PCR and immunohistochemistry. Interleukin-1beta (IL-1beta) may play an important role in the destruction of cartilage matrix in arthritis, whereas transforming growth factor-beta (TGFbeta) may have an opposing effect and their combined actions may modulate chondrocyte phenotype. The effect of rhIL-1beta and rhTGFbeta on the production of type II collagen by chondrocytes in culture was investigated. It was shown that TGFbeta enhanced the production of type II collagen, localized immunocytochemically, in cultured chondrocytes. IL-1beta inhibited expression of mRNA for type II collagen. The implications of this study, in terms of a better understanding of degenerative cartilage disease, are discussed.
THAVARAJAH M, EVANS DB, KANIS JA, 1993, DIFFERENTIATION OF HETEROGENEOUS PHENOTYPES IN HUMAN OSTEOBLAST CULTURES IN RESPONSE TO 1,25-DIHYDROXYVITAMIN-D3, BONE, Vol: 14, Pages: 763-767, ISSN: 8756-3282
EVANS DB, THAVARAJAH M, BINDERUP L, et al., 1991, ACTIONS OF CALCIPOTRIOL (MC-903), A NOVEL VITAMIN-D3 ANALOG, ON HUMAN BONE-DERIVED CELLS - COMPARISON WITH 1,25-DIHYDROXYVITAMIN-D3, JOURNAL OF BONE AND MINERAL RESEARCH, Vol: 6, Pages: 1307-1315, ISSN: 0884-0431
THAVARAJAH M, EVANS DB, KANIS JA, 1991, 1,25(OH)2D3 INDUCES DIFFERENTIATION OF OSTEOCLAST-LIKE CELLS FROM HUMAN BONE-MARROW CULTURES, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol: 176, Pages: 1189-1195, ISSN: 0006-291X
EVANS DB, THAVARAJAH M, KANIS JA, 1991, IMMUNOREACTIVITY AND PROLIFERATIVE ACTIONS OF BETA-2 MICROGLOBULIN ON HUMAN BONE-DERIVED CELLS-INVITRO, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol: 175, Pages: 795-803, ISSN: 0006-291X
THAVARAJAH M, EVANS DB, BINDERUP L, et al., 1990, 1,25(OH)2D3 AND CALCIPOTRIOL (MC903) HAVE SIMILAR EFFECTS ON THE INDUCTION OF OSTEOCLAST-LIKE CELL-FORMATION IN HUMAN BONE-MARROW CULTURES, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol: 171, Pages: 1056-1063, ISSN: 0006-291X
EVANS DB, THAVARAJAH M, KANIS JA, 1990, INVOLVEMENT OF PROSTAGLANDIN-E2 IN THE INHIBITION OF OSTEOCALCIN SYNTHESIS BY HUMAN OSTEOBLAST-LIKE CELLS IN RESPONSE TO CYTOKINES AND SYSTEMIC HORMONES, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol: 167, Pages: 194-202, ISSN: 0006-291X
EVANS DB, THAVARAJAH M, USKOKOVIC MR, et al., 1990, INCREASED POTENCY OF 1,25-DIHYDROXYVITAMIN-D3 ON HUMAN OSTEOBLAST-LIKE CELLS FOLLOWING STRUCTURAL SIDE-CHAIN MODIFICATION, BONE, Vol: 11, Pages: 439-443, ISSN: 8756-3282
KANIS JA, MCCLOSKEY EV, THAVARAJAH M, et al., 1988, CALCIUM-METABOLISM AND MYELOMA AND THE TREATMENT OF HYPERCALCEMIA, HEMATOLOGICAL ONCOLOGY, Vol: 6, Pages: 115-117, ISSN: 0278-0232
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.